Charles Ng

California Institute of Technology — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index3.4kcitations63works0.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(29), CAR-T cell therapy research(27), Immunotherapy and Immune Responses(17), Virus-based gene therapy research(16), Cutaneous Melanoma Detection and Management(13)

Publications63 total

PCR49 A Preliminary Comparison between Analytical Hierarchy Process and Discrete Choice Experiment in Health State Preferences in Hong Kong SAR, China

Value in Health·2023

PCR269 Detecting Changes in Relative Weighting of EQ-5D Dimensions and Levels with Sequential Analytical Hierarchy Process in Hong Kong Sar, China

Value in Health·2023Open Access

Supplementary Tables 1 - 5 from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy

2023Open Access

Supplementary Figures from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition

2023Open Access

Data from BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

2023Open Access

Data from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy

2023Open Access

Supplementary Tables 3, 5, 6, 8 from BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

2023Open Access

Data from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition

2023Open Access

Supplementary Figures 1-11 from BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

2023Open Access

Data from BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

2023Open Access

Supplementary Figures 1 - 8 from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy

2023Open Access

Supplementary Tables 1-2, 4, 7, 9, 10-11 from BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

2023Open Access

Supplementary Figure Legends 1-11 from BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

2023Open Access

Supplementary Tables 1 - 5 from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy

2023Open Access

Supplementary Table S1 from A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition

2023Open Access

Supplementary Figures 1-11 from BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

2023Open Access

Supplementary Methods from BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

2023Open Access

Supplementary Methods from BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

2023Open Access

Supplementary Tables 3, 5, 6, 8 from BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

2023Open Access

Supplementary Figure Legends 1-11 from BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

2023Open Access

page 1 of 4Next →

Frequent Co-authors

Antoni Ribas(46), John A. Glaspy(29), Richard C. Koya(27), Thinle Chodon(26), Earl Avramis(25), Bartosz Chmielowski(24), Alistair J. Cochran(22), Zhongqi Wu(21), James R. Heath(21), Owen N. Witte(21), David Baltimore(21), James S. Economou(21), Mohammad Atefi(18), Begoña Comı́n-Anduix(17), Tara A. McCannel(17), Caius G. Radu(17), Martin Auerbach(16), Elizabeth Seja(16), Arturo Villanueva(16), Akira Ishiyama(16)